Enzyme Engineering

& Industrial Fermentation

Enzymes are widely used as biocatalysts in the production or processing of a wide range of products including food, beverages, animal feeds, detergents, pharmaceuticals and textile products. Naturally occurring enzymes are often unstable or perform sub-optimally when moved from the biological to the industrial sphere.

Therefore, since the advent of protein engineering there have been efforts to improve these enzyme properties, and even to devise enzymes with novel specificities capable of producing types or quantities of metabolites not normally achievable in natural products. Such improvements or changes can often be challenging: enzyme activity depends on specific and highly complex structures, sometimes formed from multiple protein components, and requiring associated factors or metal ions to operate. Frequently, enhancing one desirable property comes at the cost of impairing another.

Mewburn Ellis has a long history of working with our clients in this fast-moving and competitive field. For example, we’ve been involved in protecting the ground-breaking innovations on the serine protease subtilisin (used for example in detergents and in food processing) since 1980s, and in multiple other enzymes in different fields such as brewing, biofuels and biopolymers. The Mewburn team has regularly and successfully defended patents covering our clients’ enzyme technologies at the EPO and assisted them in enforcing those patents before national courts. Engineered enzymes are typically produced in host species such as bacteria, yeasts and filamentous fungi and we also have many years’ experience in dealing with the fermentation technologies used for growing these microorganisms, and recovering the enzymes from them, whether at laboratory or industrial scale.

As more and more powerful computation tools are developed for determining and modelling protein structures, so protein engineers are increasingly able to analyse the structure-function characteristics for rationale design of novel enzymes, which can then be tested in large scale functional screening processes. Once again, our specialised team here is able to assist at our clients with obtaining protection for their intellectual property in the latest bioinformatics innovations in the enzyme space.

Open pages of Green IP Report

Green IP Report

Patents are both a driver and a barometer of innovation

Our report examines the role of patents in making innovative ‘green’ technologies into a reality as well as how the patent landscape can be used to identify opportunities for partnering, collaboration and investment.

We share our enthusiasm and admiration for commercially-focused innovation across a diverse range of technologies, from repurposing carbon dioxide to make protein-rich foods, to the multi-faceted approach to a circular plastics economy. We also discuss the tantalising prospect of AI-mediated renewable energy supply, and the harnessing of battery tech from the EV boom to drive energy efficiency in consumer devices. This report reflects our passion for technology solutions that tackle our shared global challenge.

Download the Report

Read our Blogs

The UPC going into 2026 – three key takeaways

The UPC going into 2026 – three key takeaways

by Matthew Naylor

2026 Week 1 2025 was a seriously busy year for the UPC. We came into the year with one case management system and we left it with a shiny new one. We go into 2026 with a new court fee schedule. In ...

Careful with that saisie application

Careful with that saisie application

by Matthew Naylor

2025 Week 52 They can be conveniently bundled together informally as “provisional measures” at the UPC. But orders for preserving evidence (saisie orders) and preliminary injunctions are different in ...

When success does not mean survival – Generics knock out Sanofi’s cancer drug patent at the UPC

When success does not mean survival – Generics knock out Sanofi’s cancer drug patent at the UPC

by Julie Carlisle

2025 Week 51 Generic pharmaceutical companies scored their first big win at the UPC last week, with the Munich Local Division (LD) revoking Sanofi’s patent EP 2493466 B1 for a medical use of the ...

The Vaginal Microbiome – the hidden key to success in IVF?

The Vaginal Microbiome – the hidden key to success in IVF?

by Natalie Vaughan

In vitro fertilisation (IVF) as the names suggests, is a fertility treatment where an egg is fertilised by a sperm outside of the body. For many couples diagnosed with infertility, IVF offers hope of ...

30 months in – UPC case load, locations and languages

30 months in – UPC case load, locations and languages

by Matthew Naylor

2025 Week 50 A niche skill of patent attorneys is to be able to think in blocks of 30 months. The UPC opened its doors for business on 1 June 2023 and the 30 month milestone duly rolled around at the ...

UPC first instance decisions on inventive step after Court of Appeal guidance

UPC first instance decisions on inventive step after Court of Appeal guidance

by Matthew Naylor

2025 Week 49 Last week, we reported on the landmark Amgen v. Sanofi / Regeneron and Edwards v. Meril 25 November 2025 decisions from the UPC Court of Appeal (CoA), which together set out the ...

Learn More
Forward Magazines Overlapping 8

Mewburn Ellis

FORWARD MAGAZINE

Mewburn Ellis Forward is a biannual publication that celebrates the best of innovation and exploration. Through its pages we hope to inform and entertain, but also to encourage discussion about the most compelling developments taking place in the scientific and entrepreneurial world. Along the way, we’ll engage with the IP challenges that international organisations face every day.